Daybreak Ozempic sparked the weight-loss drug trend. Mounjaro is leading it in India
Oct 9, 2025
Eli Lilly's Mounjaro has skyrocketed to become India's second-best-selling drug, marking a significant victory in the weight-loss market. With a $1 billion investment for a new manufacturing hub in Hyderabad, the competition is heating up as local pharma prepares for cheaper GLP-1 generics. The conversation dives into why diabetes medications have morphed into weight-loss wonders and the unique properties that set Mounjaro apart scientifically. Yet, hurdles like regulatory compliance and skepticism loom large in this evolving landscape.
AI Snips
Chapters
Transcript
Episode notes
Rapid Market Rise
- Mounjaro became India's second-biggest pharma brand six months after launch, recording Rs. 80 crore in revenue.
- Eli Lilly then announced a $1 billion investment and a Hyderabad manufacturing and quality hub.
Legalization Sparked A Boom
- Legal availability of GLP-1 injectables in India triggered major launches and market growth nearing Rs 600 crore.
- The category ballooned by almost Rs 100 crore after legalization and new brand entries.
India Is A Strategic Market
- India has a massive addressable market with high obesity and diabetes prevalence, making Lilly's investment strategically sensible.
- The move helps Lilly stay close to a key market and manage regulatory navigation.